On February 6, 2025 Caris Life Sciences (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, reported that the company and collaborators within the Caris Precision Oncology Alliance (Caris POA) will collectively present three studies at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers (ASCO GU) Symposium, February 13-15, in San Francisco (Press release, Caris Life Sciences, FEB 6, 2025, View Source [SID1234650091]). The findings demonstrate the continued and expanded capabilities of Caris’ comprehensive database to enable novel insights into cancer that could have profound effects on a patient’s diagnosis, prognosis, care plan and response to treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are proud to present innovative research for prostate cancer and urothelial carcinoma at the upcoming ASCO (Free ASCO Whitepaper) GU meeting," said James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance. "Through our comprehensive molecular profiling, powerful database and in-depth collaboration with Caris POA members, we are pushing the boundaries of precision medicine and helping improve outcomes for cancer patients."
Caris will present three posters at the ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium:
Evaluating molecular alteration profiles to distinguish intraductal carcinoma of the prostate
Poster Session A | Poster Board L3 | Abstract 407
February 13; 11:25 a.m. – 12:45 p.m. PST
Downregulation of E-selectin and contributions to immune restraining in prostate cancer
Poster Session A | Poster Board G30 | Abstract 257
February 13; 11:25 a.m. – 12:45 p.m. PST
Real-world analysis of 2IR immune response score in urothelial carcinoma (UC)
Poster Session B | Poster Board D36 | Abstract 739
February 14; 11:30 a.m. – 12:45 p.m. PST
Poster and abstract summaries highlighting this research will be available onsite at Caris’ booth (#32). The full abstracts will be available on the Caris website beginning on February 13.
The Caris POA includes 96 cancer centers, academic institutions, research consortia and healthcare systems, including 47 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. Caris and POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.